Verona Pharma has entered into a global services agreement with QuintilesIMS, provider of biopharmaceutical development and commercial outsourcing services.
Verona is a clinical-stage biopharmaceutical company focused on developing and commercialising therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
The services agreement establishes an operational platform to facilitate Verona’s global clinical trial-related activities for the development of its product candidate RPL554 for the treatment of COPD (chronic obstructive pulmonary disease) and cystic fibrosis.
Quintiles will serve as sole provider of core clinical trial services for Verona Pharma’s RPL554 clinical development programmes.
Verona’s product candidate is an inhaled, dual PDE3/PDE4 inhibitor that acts as both a bronchodilator and an anti-inflammatory agent in a single compound.
The company is currently developing RPL554 for the maintenance treatment of COPD patients and as an add-on therapy to commonly-used therapies for the treatment of hospitalised patients with acute exacerbations of COPD.
It is also developing RPL554 for the treatment of patients with cystic fibrosis.
